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Abstract 
Background: Evidence for effective treatment options for orthostatic hypotension (OH) in Parkinson`s disease 
(PD) is scarce. Elevation of cholinergic tone with Pyridostigmine bromide has been reported as a way to improve 
blood pressure (bp) regulation in neurogenic hypotension without causing supine hypertension.   
Methods: Double-centre, double blind, randomized, active-control, crossover, phase II non-inferiority trial of 
Pyridostigmine bromide for OH in PD (clinicaltrials.gov NCT01993680). Patients with confirmed OH were 
randomized to 14 days 3x60mg/d Pyridostigmine bromide or 1x0.2mg/d Fludrocortisone before crossover. 
Outcome was measured by peripheral and central bp monitoring during Schellong manoeuvre and 
questionnaires.  
Results: Thirteen participants were enrolled between 04/2013 and 04/2015 with 9 participants completing each 
trial arm. Repeated-measures comparison showed a significant 37% improvement with Fludrocortisone for the 
primary outcome diastolic bp drop on orthostatic challenge (baseline 22.9±13.6 vs. Pyridostigmine bromide 
22.1±17.0 vs. Fludrocortisone 14.0±12.6 mmHg; p=0.04), while Pyridostigmine bromide had no effect. 
Fludrocortisone caused an 11% peripheral systolic supine (baseline 128.4±12.8 vs. Pyridostigmine bromide 
130.4±18.3 vs. Fludrocortisone 143.2±10.1; p=0.01) but no central mean arterial supine bp rise (baseline 
107.2±7.8 vs. Pyridostigmine bromide 97.0±12.0 vs. Fludrocortisone 107.3±6.3; p=0.047). Subjective OH 
severity, motor score and quality of life remained unchanged by both study interventions.  
Conclusions: Pyridostigmine bromide is inferior to Fludrocortisone in the treatment of OH in PD. This trial 
provides first objective evidence of efficacy of 0.2mg/d Fludrocortisone for OH in PD, causing minor peripheral 
but no central supine hypertension. In addition to peripheral bp, future trials should include central bp 
measurements, known to correlate more closely with cardiovascular risk. 
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Introduction 
 
The disease burden by autonomic dysfunction in Parkinson`s disease (PD) is increasingly recognized. 
Orthostatic hypotension (OH) is reported to have an incidence of around 30% in PD (1) and a particular high 
influence on quality of life (2), while there is only Class III evidence for therapeutic interventions (3). Current 
treatment strategies anchor at behavioural adaptations, increasing overall blood pressure (bp) by elevation of 
plasma volume or administering vasoactive agents (4). Until now however, all of these interventions for OH in 
PD are viewed as investigational (5), reflecting the lack of randomized controlled trials.  
In addition to decreased cardiovascular sympathetic innervation (6), impaired baroreflex function is a major 
factor for OH in PD (7). Elevation of cholinergic tone by Pyridostigmine bromide (PB) has been suggested to 
strengthen both limbs of the baroreflex without causing supine hypertension (8). Results from a trial in a cohort 
of patients with neurogenic OH were promising (8). We therefore aimed at studying the effect of PB on OH in a 
PD cohort. A non-inferiority design was chosen with Fludrocortisone (FC), a synthetic mineralocorticoid widely 
available and used, as an active comparator. Open-label studies in small samples have suggested that FC 
improves OH in multiple system atrophy (9) and in levodopa induced OH (10), while the only randomized 
controlled trial in PD showed an effect on subjective OH symptom severity but not blood pressure measurements 
(11).  
 
 
Methods 
 
This double-centre, double blind, randomized, active-control, crossover, phase II non-inferiority trial was 
conducted in accordance with national and international law and good clinical practice. It was registered locally 
and internationally (clinicaltrials.gov NCT01993680). The study protocol was approved by the Zurich cantonal 
ethics committee and the national medical regulatory body Swissmedic. All participants provided written 
informed consent for participation prior to inclusion. The study was designed with diastolic bp drop on 
Schellong maneuver (mmHg) as the primary outcome measure. Power calculations were based on effect sizes for 
PB in neurogenic OH (8) with a non-inferiority margin M of 50%. For an effect size of 2.45 and a calculated 
error probability of α = 0.05 (resulting power (1-β) = 0.95), an overall sample size of n=10 participants was 
calculated to prove non-inferiority (critical t 1.86; actual power 0.97) – to increase power, we aimed at n=18. 
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Participant Selection 
PD patients diagnosed according to UK Brain bank criteria, 50-80 years of age, Hoehn & Yahr stages 2 and 3, 
with symptomatic, established OH (≥20 mmHg drop systolic or 10mmHg diastolic peripheral bp within 3 
minutes of standing (12)) on routine follow-up were recruited from the outpatient clinics of participating centers. 
Patients on medication influencing bp regulation (antihypertensive drugs, mirtazapine, sertraline, paroxetine, 
fluoxetine, venlafaxine, trazodone, anticholinergics, etc.), depolarizing muscle relaxants, with systemic disease 
(diabetes, infection, renal or kidney failure, malignancy), pathological under- or overweight and conditions 
interfering with compliance were excluded. Furthermore, patients presenting with signs for cerebellar 
involvement or other clinical or imaging features suggestive of multiple system atrophy (MSA) were not 
included. Participants continued their dopaminergic medication and physical hypotension measures unchanged 
throughout the study. 
 
Trial design and procedures 
Study visits were conducted directly before the first and directly after the final dose of trial medication. Trial 
arms had 14 days duration and 21 days of washout before crossover, with the biological half-life being 36 (FC), 
respective 1.5 hours (PB). All study visits included the same procedures and were conducted in the same clinical 
trial suite at ambient room temperature from 9 AM after an overnight fast. Investigations were performed after a 
minimum of 20min supine rest at 30° head elevation. Non-invasive central bp measurements were performed 
using pulse wave analysis by applanation tonometry (13) (SphygmoCor; AtCor Medical Pty., Sydney, Australia) 
– measurements with an operator index <80% were excluded. Cardiovascular monitoring was recorded 
continuously during Schellong manoeuvre (Nihon Kohden, Cham, Switzerland; 10min supine, 10min standing). 
Motor (UPDRS III), cognitive (Montreal Cognitive Assessment (MoCA) and additional domains (Hospital 
Anxiety and Depression Scale, Zurich autonomic questionnaire, OH symptom assessment (OHSA) scale (14) 
and quality of life) assessments were recorded in a standardized way. Home bp measurements in sitting position 
consisted of repeat automated morning and evening measurements (WatchBPhome, microlife, Widnau, 
Switzerland) for 7 days before study visits.  
Study medication was prepared in identical capsules by the Cantonal Pharmacy of the Canton of Zurich, which 
also performed independent randomization. Study medication was kept at 4°C by participants and was started at 
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3x30mg/d (PB) and 1x0.1mg (FC)  + 2x placebo/d for 3 days before dose increment to 3x60mg/d and 1x0.2mg/d 
+ 2x placebo/d. Compliance was monitored by drug calendars and collection of empty medication packaging.  
 
Data analysis 
All data are expressed as means and standard deviations. Data sets were included if trial arms were completed. 
Mixed linear model statistics were used for repeated measures comparison. Post-hoc analysis (LSD) was 
performed in case of significant differences between groups. A two-tailed p value of 0.05 was considered 
significant. Statistical analysis was performed using SPSS 22.0 (IBM, Armonk, NY).  
 
 
Results 
 
Thirteen participants were enrolled between 04/2013 and 04/2015 – for clinical characteristics see Table 1. 
Before the final study visit, two subjects withdrew consent due to strenuous study procedures, one received DBS 
implantation and one dropped out due to a non-study related accident. After an interim analysis of the primary 
outcome measure after the ninth completed data set (subject 13) showing futility of the primary outcome 
measure for PB, the trial was terminated and data analyzed as intention to treat. Each trial arm was fully 
completed by 9 participants and medication compliance was 99%. The pre-defined non-inferiority margin M was 
missed and non-inferiority rejected.  
Outcome variables of the intention-to treat analysis are displayed in Table 2 and Figure 1. FC improved the 
primary outcome measure diastolic bp drop on Schellong maneuver by 37% (p=0.016), as well as minimal mean 
arterial bp standing by 15% (p=0.02), whereas PB treatment had no significant effect (Figure 1A, B). Subjective 
symptom severity was not changed by any intervention (Figure 1E) and did not correlate with changes in bp drop 
on Schellong (ns). Peripheral systolic bp supine (Figure 1C) and systolic 7d home bp measurement sitting were 
increased by 11% after FC (p=0.004) but not PB treatment. Central mean supine bp was lowered by 9% by PB 
(p=0.03) but remained unchanged after FC treatment (Figure 1D). Neither drug had any influence on motor, 
cognitive and neuropsychiatric measure or quality of life. Stool consistency was significantly softened with PB 
treatment (p=0.015), while neither treatment had an influence on the subjective severity of other autonomic 
symptoms. While PB lowered Sodium levels (p=0.009), Potassium levels were unchanged in both trial arms 
(Figure 1F, G). 
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Transient, mild adverse events were reported during PB (dizziness, n=1; mouth dryness, n=1; transient increase 
of motor off phase n=1) and FC treatment (leg oedema, n=1) without leading to dose adjustment or drop-out.  
There was a weak positive correlation between motor and subjective OH symptoms among participants (Figure 1 
H; r2=0.38, p=0.03). 
 
 
Discussion 
 
Futility of Pyridostigmine bromide for OH in PD 
OH is classically defined by a drop of more than 20 mmHg in systolic or 10mmHg in diastolic peripheral bp 
within 3 minutes of standing (12). Recently a mean bp (MBP) <75mmHg upon standing has been found to 
correlate better with OH symptoms in PD (15). In the present study, PB failed to display a positive effect for 
both OH definitions as well as for subjective severity of OH symptoms in PD patients. While 55% of patients 
had a net improvement of diastolic bp drop with PB (100% for FC, p=0.08), the overall mean effect size was 
negligible and did not reach the pre-set non-inferiority margin. Thus, in our homogeneous PD cohort, we could 
not reproduce the positive effect of PB on OH, as shown for a single dose of 60mg in a mixed cohort of patients 
with neurogenic OH (8) - follow-up studies of the initial report did not include PD patients (16,17). Possible 
explanations for this discrepancy could be either insufficient dosing or age- and disease-inherent factors. 
Previous studies have reported an effect of 30mg (18), 120mg (19) and 180mg (20) of PB on autonomic nervous 
system activity in healthy controls. Although having received 180mg PB per day, it cannot be excluded that this 
dose was insufficient for elevation of cholinergic tone in this population. On the other hand, the significant 
subjective softening of stool consistency and increased heart rate change on Schellong maneuver by PB suggests 
a clinically relevant effect on the autonomic nervous system. Alternatively, different OH disease mechanisms 
might influence the effect of PB on the baroreflex. The lesion site leading to OH is central and preganglionic in 
MSA, whereas it is peripheral and postganglionic in pure autonomic failure and PD (21). So far no difference in 
baroreflex testing has been reported between MSA and PD (22), suggesting that further studies into the exact 
pathophysiological mechanism of baroreflex dysfunction in these etiologies are warranted.  
Our results indicate that a reasonable therapeutic effect on OH in PD might not be achievable with PB. 
Furthermore, the finding of hyponatremia is an additional caveat for its long-term application in PD, although 
the exact mechanism underlying this phenomenon remains elusive.  
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Beneficial effect of Fludrocortisone  
In contrast, our data provide the first evidence for a significant improvement on both diastolic bp drop on 
orthostatic challenge (-37%) and MBP standing (+15%) by 0,2mg FC per day in PD. As MBP and diastolic bp 
have been shown to correlate closer with symptomatic OH than systolic bp (15), we consider OH therapy with 
FC can thus be considered successful. So far a significant effect has only been shown in cohorts of diabetic OH 
and Shy-Drager syndrome, i.e. MSA (9,23). In the single previous trial of FC for OH in PD, 0.1mg FC per day 
only improved subjective symptoms but did neither change bp drop on orthostatic challenge nor supine systolic 
bp (11). Together with our observations this supports a dose-dependent effect of FC on bp regulation. The fact 
that this positive effect with 0.2mg FC per day on objective bp regulation was not reflected by significant 
changes of subjective OH symptom perception might be either due to the limited sample size, low sensitivity of 
the OHSA score or a possible dissociation of subjective vs. objective OH symptoms in this population (24).  
 
Treatment effects on central blood pressure 
As expected, 0.2mg FC per day caused an overall increase of peripheral bp levels – systolic bp in sitting and 
supine position was raised by 11%. According to suggested criteria, this constitutes supine hypertension (15), 
quoted to be the most relevant side effect of FC treatment (4,15). Although frequently quoted, there is no clear 
definition of supine hypertension, leading to different cut off values applied to study data in the literature 
(15,25). Our finding of unchanged central bp with FC treatment however shed light on another, novel aspect in 
the interpretation of supine hypertension in PD. The elastic properties of the arterial system and its branches 
cause the central bp to be amplified in the periphery and while the bp in the central arteries directly governs the 
load on the heart, this is not directly reflected by peripheral bp (26). There is compelling empirical evidence 
showing that central bp is superior in predicting cardiovascular disease risk in comparison to peripheral bp 
(26,27). To our knowledge, central bp has not been reported in PD patients before (11,16,25). Although further 
studies into central bp in PD therefore seem warranted, the finding of unchanged central bp under FC treatment 
might indicate a more favorable side effect profile than anticipated. In contrast to previous reports, we did not 
observe any electrolyte disturbances and in particular hypokalemia with FC use.  
 
Limitations and Conclusion 
We acknowledge the number of participants and dropout rate in this trial as a weakness that warrants replication. 
Future trials with similarly strict in- and exclusion criteria will likely need a multi-center approach (25), as 
recruitment was more difficult than anticipated. Although we excluded alternative pharmacological influence on 
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bp, dopaminergic medication of course influenced bp regulation (28). However, measurements in the OFF state 
were deemed unfeasible and we think that measurements in the ON state more closely resemble clinical reality. 
Independent of this it is important that pharmacological therapy of OH should always be preceded by the 
exhaustion of non-pharmacological measures. 
This trial however provides first evidence for the efficacy of 0.2mg/d FC for OH in PD, which is a confirmation 
of frequent clinical practice. The observed effect size with FC treatment is of note compared to recent much 
larger trials for OH in PD that did not show a persistent benefit on bp regulation (25). We also show first 
evidence that supine hypertension in the periphery might not reflect central bp changes in PD. Additional studies 
are needed to clarify the significance of central bp and supine hypertension in the cardiovascular risk assessment 
in PD.  
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Figure and Table captions: 
Fig.1 Effect of study medication on diastolic blood pressure drop standing (a), minimal mean blood pressure 
standing (b), supine systolic peripheral (c) and supine mean central (d) blood pressure, severity of subjective OH 
symptoms (e) and electrolyte levels (f, g). Parkinson´s disease motor symptoms correlated weakly with 
subjective OH symptoms (h). 
 
Table 1 Study population baseline characteristics. 
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Table 2 Effect of Pyridostigmine bromide and Fludrocortisone on blood pressure regulation, motor symptoms 
and other autonomic domains in study participants (n=13) 
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Table 1 Study population baseline characteristics 
 
No. Sex/age UPDRSIII ON MoCA LED (mg/d) Diastolic bp drop on 
Schellong (mmHg) 
minimum standing 
mean bp 
OHSA 
1 M / 73 15 26 865 27 67 10 
2 F / 77 17 29 600 15 110 9 
3 M / 78 19 24 1000 10 87 23 
4 M / 65 15 25 600 24 66 9 
5 M / 72 25 26 1165 21 77 11 
6 M / 60 18 29 990 30 58 9 
7 M / 79 45 20 1264 17 65 32 
8 M / 75 22 22 1250 57 32 13 
9 F / 73 23 21 685 15 86 30 
10 M / 66 29 20 1197 39 52 22 
11 M / 67 21 22 550 27 67 24 
12 M / 72 33 20 1412 18 70 17 
13 M / 70 32 27 785 17 81 18 
Mean ± SD 71.3 ± 5.6 24.2 ± 8.6 23.9 ± 3.3 947 ± 295 22.9 ± 13.6 70.7 ± 18.8 17.8 ± 8.4 
Abbreviations: UPDRSIII – United Parkinson`s disease rating scale part III; MoCA - Montreal Cognitive Assessment; LED – levodopa equivalent dose (according to (29));  
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Table 2 Effect of Pyridostigmine bromide and Fludrocortisone on blood pressure regulation, motor symptoms and other autonomic domains in Parkison`s disease patients with 
symptomatic orthostatic hypotension (n=13) 
 
 
 Baseline 
Pyridostigmin 
bromide 
Fludrocortisone 
Mixed linear repeated 
measures comparison 
LSD post hoc 
comparison 
Peripheral blood pressure on Schellong manoeuvre  
Diastolic bp drop § 
(mmHg)  
22.9 ± 13.6 22.1 ± 17.0 14.0 ± 12.6 p=0.036 ‡ p=0.016 
Systolic bp drop § 
(mmHg) 
41.1 ± 16.9 36.4 ± 11.1 34.6 ± 15.2 p=0.26 n.a. 
Mean systolic bd standing 
(mmHg) 
105.0 ± 16.8  100.2 ± 18.8 112.0 ± 21.8 p=0.34 n.a. 
Mean diastolic bd standing 
(mmHg) 
71.6 ± 1.4 68.6 ±13.9 73.3 ± 15.7 p=0.62 n.a. 
Rate of improvement on 
diastolic bp drop 
n.a. 5/9 (55%) 9/9 (100%) Fisher`s Exact Test p=0.08 n.a. 
Lowest mean arterial bp 
(MBP) standing § 
70.7 ± 18.8 69.9 ± 16.4 83.9 ± 17.3 p=0.038 ‡ p=0.021, ©p=0.029 
 15 
(mmHg) 
Systolic bp supine 
(mmHg) 
128.4 ± 12.8 130.4 ± 18.3 143.2 ± 10.1 p=0.012 ‡ p=0.004;  
Diastolic bp supine 
(mmHg) 
79.9 ± 6.7 79.0 ± 9.0 84.6 ± 6.8 p=0.23 n.a. 
Heart rate increase on 
standing § 
10.1 ± 3.1 12.5 ± 4.0 9.2 ± 4.0 p=0.028 # p=0.038; ©p=0.011 
Central supine blood pressure  
Central mean bp (mmHg) 107.3 ± 7.8 97.0 ± 12.0 107.3 ± 6.3 p=0.047 # p=0.034; ©p=0.029 
Central systolic bp 
(mmHg) 
134.0 ± 14.8 122.7 ± 17.6 137.3 ± 15.3 p=0.16 n.a. 
Central diastolic bp 
(mmHg) 
88.7 ± 6.8 80.8 ± 10.6 89.0 ± 4.3 p=0.056 n.a. 
7d Home bp measurement sitting 
Systolic bp (mmHg) 123.9 ± 16.6 127.7 ± 12.0 139.9 ± 11.0 p=0.002 ‡ p=0.002; ©p=0.002 
Diastolic bp (mmHg) 74.6 ± 9.3 74.6 ± 9.8 82.3 ± 9.3 p=0.017  ‡ p= 0.031;©p=0.038 
Heart rate (bpm) 73.0 ± 7.8 69.6 ± 9.3 71.3 ± 6.9 p=0.73 n.a. 
Overall motor, cognitive and neuropsychiatric functioning and Quality of life 
UPDRSIII 24.2 ± 8.6 24.0 ± 10.5 22.1 ± 10.7 p=0.93 n.a. 
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MoCA 23.9 ±3.3 24.1 ± 5.0 25.3 ± 2.7 p=0.61 n.a. 
HADS A 5.1 ± 2.9 4.13 ± 2.7 5.6 ± 5.2 p=0.89 n.a. 
PDQ-39 sum index 24.9 ± 18.6 22.6 ± 12.8 22.3 ± 17.7 p=0.55 n.a. 
Subjective severity of autonomic symptoms 
OHSA 17.8 ± 8.4 16.0 ± 10.8 16.6 ± 14.3 p=0.96 n.a. 
OHDAS 11.5 ± 6.6 10.9 ± 5.0 12.4 ± 10.6 p=0.75 n.a. 
Stool consistency $ 3.2 ± 1.5 1.8 ± 0.9 2.8 ± 1.2 p=0.028  # p=0.015; ©  
Stool frequency per day 0.4 ± 0.7 0.9 ± 0.8 0.9 ± 0.9 p=0.34 n.a. 
Urinary urgency ✝  3.1 ± 0.9 3.0 ± 0.9 3.5 ± 1.2 p=0.77 n.a. 
Urinary frequency per day 5.3 ± 1.4 6.1 ± 2.2 4.8 ± 2.6 p=0.54 n.a. 
Subjective drooling ✝  2.2 ± 1.0 2.4 ± 1.3 2.0 ± 1.2 p=0.29 n.a. 
Dizziness on rising ✝  2.9 ± 0.8 2.4 ± 0.9 2.3 ± 1.0 p=0.14 n.a. 
Electrolytes 
Potassium (mmol/l;  
norm: 3.3 - 4.5) 
3.9 ± 0.29 4.0 ± 0.29 4.0 ± 0.17 p=0.64 n.a. 
Sodium (mmol/l;  
norm: 136 - 145) 
139.7 ± 2.0 136.7 ± 4.1 139.7 ± 2.6 p=0.013 # p=0.009; © p=0.01 
# baseline vs. Pyridostigmine bromide; ‡ baseline vs. Fludrocortisone; © Pyridostigmine bromide vs. Fludrocortisone; Abbreviations: UPDRSIII – Unified Parkinson`s disease 
rating scale part III; MoCA - Montreal Cognitive Assessment; LED – levodopa equivalent dose (according to (29)); OHSA – Orthostatic Hypotension Severity Assessment; 
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OHDAS - Orthostatic Hypotension  Daily Activity Scale; § between 0 and 3 min standing; Zurich Autonomic Questionnaire using a 5 point likert scale from 0 to 5 indicating 
soft to hard ($), respectively little to severe symptom intensity (✝ ) ; 
 
